Aging dramatically reshapes how our bodies process nutrients and energy—a signature that shows up clearly in blood metabolite patterns. This study investigated whether losartan, an angiotensin II receptor blocker used for decades to treat high blood pressure, could reverse some of these age-related metabolic changes. The researchers used two complementary approaches: controlled experiments in aged mice and data from a phase 2 randomized placebo-controlled trial in pre-frail older men, analyzing hundreds of metabolites simultaneously.
In mice, losartan treatment shifted the serum metabolome (the collection of small molecules in blood) toward patterns resembling younger animals. This effect was mechanistically specific: when researchers used genetically modified mice lacking functional angiotensin II receptors, losartan produced no rejuvenation effect, proving the drug works through this particular pathway rather than as a general antioxidant or metabolic stimulant. Similar rejuvenation appeared in cardiac proteins, particularly those involved in energy production (oxidative phosphorylation). Notably, geriatric mice treated with losartan showed statistically significant survival improvements, though the paper does not present complete lifespan curves.
Human data from the phase 2 trial showed dose-dependent metabolic rejuvenation—stronger effects at higher doses—paralleling the mouse findings. However, species differed strikingly: mouse metabolism showed broad decreases in metabolite levels with age, while human aging was marked by increases, especially in lipid species. This divergence hints at fundamental differences in how rodent and human physiology age, likely related to lipoprotein metabolism, plasma volume shifts, and amino acid handling.
Key limitations deserve emphasis: this is not a full lifespan study in mice, so survival benefit remains preliminary and awaits confirmation. The human trial was phase 2 (typically small, proof-of-concept stage) with pre-frail participants—results may not generalize to healthy older adults or younger populations. The paper measures metabolic biomarkers, not clinical outcomes like physical function, frailty reduction, or disease prevention. Cross-species metabolomic differences underscore that mouse models don't always predict human responses. No information is provided on trial duration, exact sample sizes for human data, or potential confounders.
This work fits into a broader effort to repurpose existing drugs for aging. Losartan is already widely used, inexpensive, and has a long safety record—attractive features for any potential geroprotector. The mechanistic specificity (requiring angiotensin II receptors) strengthens the case that the effect is real rather than artifact. However, metabolomic rejuvenation is a biomarker, not proof of lifespan or healthspan extension in humans. The next steps should include larger, longer-duration randomized trials measuring clinical endpoints: physical function, frailty scores, hospitalization rates, or mortality.
For longevity research, this paper exemplifies rigorous multi-omics science applied to drug repurposing and highlights how systemic aging involves tractable metabolic pathways. The angiotensin II system regulates blood pressure, inflammation, and metabolic homeostasis—all known aging hallmarks—making it a plausible target. Yet skepticism is warranted: metabolomic changes alone have never been validated as true aging biomarkers, and rodent lifespan studies (even preliminary ones) often don't translate to human lifespan benefit.
0 Comments
Log in to join the discussion.